Relief Therapeutics Holding AG (RLFTF)

[nelskof]

Check out the wording used here:

VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100™ for the treatment of COVID-19 and awarded Fast Track designation. RLF-100™ is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100™ under FDA-approved protocols.

That is very strong language. Over 150 patients! That's a lot of data.

1. inhibits coronavirus replication
2. blocks the formation of inflammatory cytokines
3. prevents cell death
4. upregulates the production of surfactant